Drug Topics
DECEMBER 7, 2023
A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
STAT
DECEMBER 7, 2023
TIJUANA, Mexico — Just over a decade ago, when Crystal Pérez Lira needed an abortion, she had to leave Mexico. The procedure was illegal in her home state of Baja California and so deeply stigmatized that even Pérez Lira supported the procedure only for those who were raped. Until she unexpectedly got pregnant. She traveled to the U.S. for help, walking alone across the border from Tijuana to San Diego, first for a health check and a compulsory ultrasound, and then back for a se
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
DECEMBER 7, 2023
Two posters presented at ASHP 2023 Midyear examined how accurate answers were from the artificial intelligence chatbot.
Pharmacy Times
DECEMBER 7, 2023
The study authors note that addressing environmental factors, such as IPV and food insecurity, can provide further benefits in neurodevelopment regardless of maternal HIV status.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 7, 2023
The two leaders of the Senate Budget Committee on Thursday launched a bipartisan investigation into private equity ownership of hospitals in the United States, citing concerns that such arrangements are bad for both health care providers and patients. “As private equity has moved into health care, we have become increasingly concerned about the associated negative outcomes for patients,” said Chairman Sheldon Whitehouse (D-R.I.) in a statement.
Drug Topics
DECEMBER 7, 2023
By identifying areas of improvement and offering recommendations based on a prior cycle, investigators developed a new Plan-Do-Study-Act (PDSA) cycle to meet standards of USP.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
DECEMBER 7, 2023
Both the executive branch and key bipartisan legislators announced plans Thursday to tackle the negative impacts of corporate interests and ownership in healthcare. | Multiple federal agencies and bipartisan Senate leaders have launched a salvo of efforts targeting anticompetitive behaviors, high prices and private equity-involvement in the healthcare industry.
Fierce Pharma
DECEMBER 7, 2023
When it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinely tripped up even the industry's l | In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation.
STAT
DECEMBER 7, 2023
Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news comes three months after Insulet, EOFlow’s rival, filed a lawsuit accusing the company of stealing trade secrets. In a filing with the Securities and Exchange Commission late Wednesday, Medtronic announced its cancellation of the deal. The filing is vague, citing “multiple breaches under the agreements” that allow Medtronic to renege.
Pharmacy Times
DECEMBER 7, 2023
Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
Pharmacy Times
DECEMBER 7, 2023
The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.
STAT
DECEMBER 7, 2023
Many families take for granted the ritual of taking a newborn baby home, car seat and curated swaddle blankets in tow, just a few days after delivery. But as critical care pediatricians, we care for babies and children who often don’t fit neatly into these universal experiences. When our patients go home for the first time, they are rarely newborns.
pharmaphorum
DECEMBER 7, 2023
Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
DECEMBER 7, 2023
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. March-in mania The White House today will take a long-awaited step to potentially broaden the government’s authority to undermine patents for medicines developed with taxpayer funding — including considering a drug’s price as one part of the framework, my co-aut
Drug Store News
DECEMBER 7, 2023
CVS and Rite Aid are among the retailers offering customers gift ideas galore for the holidays, while Albertsons is kicking off savings for food, toys, meals and more and Target is offering low cost holiday meals and gifts.
pharmaphorum
DECEMBER 7, 2023
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.
STAT
DECEMBER 7, 2023
Will this be a half a loaf? After months of deliberation, the Biden administration on Thursday asserted its authority to sidestep patents in order to lower costs for some pricey medicines that were discovered with taxpayer money. But the move, which must still be finalized by an inter-agency working group, is already causing uncertainty over the extent to which drugmakers may lose valuable monopolies and consumers will save money.
pharmaphorum
DECEMBER 7, 2023
In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with David Solomon, CEO of Mithra Pharmaceuticals, about the current women’s health landscape and what Mithra is doing on an international scale to ameliorate that.
Drug Store News
DECEMBER 7, 2023
Retailers, including Walgreens and Kinney Drugs are reminding consumers about flu and COVID-19 immunizations and testing offerings as the U.S. heads into peak respiratory illness season.
pharmaphorum
DECEMBER 7, 2023
Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.
European Pharmaceutical Review
DECEMBER 7, 2023
Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. baricitinib… [demonstrated an ability to] preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis” The researchers noted that baricit
Fierce Pharma
DECEMBER 7, 2023
In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. | In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson.
STAT
DECEMBER 7, 2023
White House officials will take more time to review a sweeping plan from U.S. health regulators to ban menthol cigarettes , an unexpected delay that anti-tobacco groups fear could scuttle the long-awaited rule. Administration officials indicated Wednesday the process will continue into next year, targeting March to implement the rule, according to an updated regulatory agenda posted online.
Fierce Pharma
DECEMBER 7, 2023
Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). | Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames.
pharmaphorum
DECEMBER 7, 2023
Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.
Fierce Pharma
DECEMBER 7, 2023
It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. | It’s been more than three years since Bristol Myers Squibb’s powerhouse immuno-oncology combination treatment of Opdivo and Yervoy has scored a combined FDA approval. But the duo could be on its way to a new endorsement based on a phase 3 trial that shows it can keep certain first-line colorectal cancer patients alive longer than
Drug Store News
DECEMBER 7, 2023
Dollar General's same-store sales in the third quarter of 2023 included declines in each of the home, seasonal, apparel and consumable categories.
STAT
DECEMBER 7, 2023
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us.
PharmExec
DECEMBER 7, 2023
Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.
STAT
DECEMBER 7, 2023
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future.
Fierce Pharma
DECEMBER 7, 2023
WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. | WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute.
Drug Store News
DECEMBER 7, 2023
CVS and Rite Aid are among the retailers offering customers gift ideas galore for the holidays, while Albertsons is kicking off savings for food, toys, meals and more.
Pharmacy Times
DECEMBER 7, 2023
Improvements in PFS were also seen among patients with brain metastases.
Expert insights. Personalized for you.
232 
Let's personalize your content